{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Palisade Bio, Inc.
Is Palisade Bio, Inc. technically bullish or bearish?
As of April 24, 2025, the trend is mildly bearish due to daily moving averages indicating bearish momentum, despite some bullish signals from weekly indicators like MACD and KST.
Who are in the management team of Palisade Bio, Inc.?
As of March 2022, the management team of Palisade Bio, Inc. includes Dr. Kenneth Carter as Executive Chairman and Principal Executive Officer, with board members Dr. Mary Gray, Dr. David Mazzo, Dr. Cristina Csimma, Mr. Scott Ogilvie, and Mr. Sandford Smith, the latter three serving as independent directors.
What does Palisade Bio, Inc. do?
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs. It has a market cap of $3.09 million and reported a net profit loss of $2 million as of March 2025.
How big is Palisade Bio, Inc.?
As of Jun 18, Palisade Bio, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million with a net profit of -13.14 million over the last four quarters. Shareholder's funds are at 7.49 million and total assets at 10.88 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
